Can I stop taking crizotinib after taking it for 6 years?

Crizotinib, as a targeted therapy drug, plays an important role in the treatment of non-small cell lung cancer (NSCLC), especially for patients with ALK gene rearrangements or ROS1 gene fusions.

Crizotinib can significantly extend patients' progression-free survival (PFS), and in some cases, patients may have long-term responses to the drug. However, each patient's response is different, and some patients may remain sensitive to the drug after prolonged treatment, while others may develop resistance.

After long-term use of crizotinib, some patients may develop drug resistance. This usually manifests as stable disease or shortened remission period, increased tumor markers, or the emergence of new tumor lesions. If these conditions occur, doctors may recommend genetic testing to confirm the presence of drug-resistant mutations and adjust treatment based on the results.

Before considering discontinuing medication, patients should undergo a thorough evaluation, including physical condition, disease stability, and physician advice. Sudden discontinuation of medication may cause the condition to rebound or accelerate progression, so it must be done under close monitoring and guidance by a doctor.

If the patient and doctor decide together to discontinue the drug, a gradual tapering strategy is often recommended rather than stopping the drug suddenly and completely. Doing so reduces the body's reaction to sudden withdrawal of the drug and allows doctors to closely monitor any possible changes in the condition.

After discontinuation of medication, patients should continue to receive regular medical examinations and monitoring to ensure the stability of their condition. If signs of recurrence are found, the doctor may recommend resumption of treatment or a different treatment plan.